Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM) Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG)...

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modalityBelieved to be the first ever AAV...